Cellectar Biosciences to Host Conference Call with Texas Oncology Hematologist M. Yair Levy, M.D. on January 19, 2024 to Discuss Iopofosine I 131 Pivotal Topline Results

January 12, 2024

https://www.globenewswire.com/news-release/2024/01/12/2808536/0/en/Cellectar-Biosciences-to-Host-Conference-Call-with-Texas-Oncology-Hematologist-M-Yair-Levy-M-D-on-January-19-2024-to-Discuss-Iopofosine-I-131-Pivotal-Topline-Results.html

FLORHAM PARK, N.J., Jan. 12, 2024 (GLOBE NEWSWIRE) — Cellectar Biosciences, Inc. (NASDAQ:CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced it will host a conference call with M. Yair Levy, M.D., director of hematologic malignancies research at Texas Oncology and investigator in the CLOVER WaM pivotal study of iopofosine I 131, on Friday, January 19, 2024 at 8:30 a.m. ET.

Read more at globenewswire.com

Related news for (CLRB)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.